课题基金 / 基金详情

HLA restricted tumor specific antigen epitope pulsed autologous dendritic cell vaccine treatment for hormone refractory prostate cancer

HLA restricted tumor specific antigen epitope pulsed autologous dendritic cell vaccine treatment for hormone refractory prostate cancer
HLA限制性肿瘤特异性抗原表位脉冲自体树突状细胞疫苗治疗激素难治性前列腺癌
批准号:
12671557
负责人:
TACHIBANA Masaaki
金额:
$2.56万
依托单位:
依托单位国家:
日本
项目类别:
Grant-in-Aid for Scientific Research (C)
财政年份:
2000
资助国家:
日本
项目状态:
已结题
起止时间:
2000 至 2001

项目摘要

项目成果

TACHIBANA Masaaki的其他基金

相似基金

相关文献

中文摘要
翻译
前列腺特异性膜抗原(PSMA)是一种主要在前列腺癌中表达的跨膜糖蛋白,是肿瘤特异性免疫治疗的靶点。为了从PSMA中筛选出人类白细胞抗原A24限制性表位多肽,为进一步应用树突状细胞(DC)为基础的肿瘤免疫治疗奠定基础,我们在体外筛选了几种PSMA编码的人类白细胞抗原A24结合多肽,以研究它们诱导特异性抗肿瘤细胞毒性T淋巴细胞(CTL)反应的能力。以人类白细胞抗原A24+健康供者外周血单核细胞来源的自体DC为抗原提呈细胞,研究了9种多肽对CD8+T细胞体外诱导的CTL反应。Lysdpadyf和NYATEDff两种多肽被鉴定为能够诱导CLT株裂解用每种多肽冲击的人类白细胞抗原A24+靶细胞。以Gen I和抗CD8单抗为靶细胞,以抗MHC II类单抗和抗CD4单抗为靶细胞,证实了CTL细胞系的抗原特异性。这些新的HLA-A-24限制性PSMA表位多肽的鉴定将为我们进一步评估基于DC的免疫治疗策略治疗激素难治性前列腺癌的临床可行性提供机会。
英文摘要
Prostate-specific membrane antigen (PSMA), a transmembrane glycoprotein predominantly expressed in prostate cancer, is an attractive target for tumor-specific immunotherapy. To identify HLA-A24-restricted epitope peptides from PSMA for further application of the dendritic cells (DC)-based immunotherapy targeting prosate cancer, we have screened several PSMA-encoded HLA-A24 binding peptides for their capabilities to elicit specific antitumor cytotoxic T-lymphocytes (CTL) response in vitro. A total of 9 peptides were studied if they could elicit CTL responses by primary in vitro immunization of CD8+ T cells using preptide-pusled autologous DC derived from peripheral blood mononuclear cells of HLA-A24+Healthy donor as antigen-presenting cells. Two peptides, Lysdpadyf and NYATEDFF, were indentified to be able to elicit CLT lines that lysed HLA-A24+target cells pulsed with each peptides. The antigen specificity of the CTL lines was confirmed utilizing several tumor cell lines as target cells, which were gen I and anti-CD8 monoclonal antibdies (mABs) bur not by anti-MHC class II and anti-CD4mABs. The identification of these novel HLA-A-24-restricted PSMA epitope peptides would provide us the opportunity to further evaluate the clinical feasibility of DC-based immunotherapeutic strategy against hormone-refractory prostate cancers.
期刊论文(23)
专著(0)
科研奖励(0)
会议论文
橘 政昭: "Microsatellite analysis in multiple chromosomal regions as a prognostic factor of primary blandoler cancer"Urol Res. 28. 293-303 (2000)
Masaaki Tachibana:“多染色体区域的微卫星分析作为原发性布兰多勒癌的预后因素”Urol Res. 28. 293-303 (2000)
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
Tachibana M.: "Autocrine growth promotion by multiple hematopoietic growth factors in the established renal cell carcinomalineKU-19-20."Cell Tissue Res.. 301(3). 353-367, (2000)
Tachibana M.:“多种造血生长因子在已建立的肾细胞癌细胞株KU-19-20中促进自分泌生长。”细胞组织研究301(3)。
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
橘 政昭: "Prognostic value of alkaline phosphate flore in patients with metastatic prostate cancer treated with endocrine Tx"Urology. 56(5). 843-847 (2000)
Masaaki Tachibana:“碱性磷酸盐花在接受内分泌 Tx 治疗的转移性前列腺癌患者中的预后价值”56(5) (2000)。
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
橘 政昭: "Immunotherapy of bladder cancer using autologus dendritic cells pulsed with HLA-A24 - specific MAGE-3 peptide"Clin Cancer Res.. 7・1. 23-31 (2001)
Masaaki Tachibana:“使用用HLA-A24-特异性MAGE-3肽脉冲的自体树突状细胞进行膀胱癌的免疫治疗”Clin Cancer Res. 7・1 (2001)。
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
共 22 条
    Tumor specific immunotherapy using dendritic cells generated from allogeneic peripheral stem cell.
    • 批准号:
      14370520
    • 项目类别:
      Grant-in-Aid for Scientific Research (B)
    • 资助金额:
      $9.22万
    • 财政年份:
      2002
    • 负责人:
      TACHIBANA Masaaki
    • 依托单位:
    Induction of apoptosis against cytokine-producing urological cancer
    • 批准号:
      10671493
    • 项目类别:
      Grant-in-Aid for Scientific Research (C)
    • 资助金额:
      $2.11万
    • 财政年份:
      1998
    • 负责人:
      TACHIBANA Masaaki
    • 依托单位:
    Establish mentofthe minimally invasive treatments based on biological characteristics for advanceduro logical cancers.
    • 批准号:
      07407046
    • 项目类别:
      Grant-in-Aid for Scientific Research (A)
    • 资助金额:
      $14.21万
    • 财政年份:
      1995
    • 负责人:
      TACHIBANA Masaaki
    • 依托单位:
    Studies on objective indicator for predicting malignant potential of bladder cancer.
    • 批准号:
      04454409
    • 项目类别:
      Grant-in-Aid for General Scientific Research (B)
    • 资助金额:
      $3.9万
    • 财政年份:
      1992
    • 负责人:
      TACHIBANA Masaaki
    • 依托单位:
    国内基金
    海外基金
    基于生物合成靶向PSMA气囊用于前列腺癌精准诊断的研究
    • 批准号:
      2026JJ70004
    • 项目类别:
      省市级项目
    • 资助金额:
      --
    • 批准年份:
      2026
    • 负责人:
      扶美君
    • 依托单位:
    PSMA4通过泛素化修饰调控PD-L1蛋白稳定性影响胃癌免疫逃逸的机制研究
    • 批准号:
      MS25H160086
    • 项目类别:
      省市级项目
    • 资助金额:
      --
    • 批准年份:
      2025
    • 负责人:
      蒋海萍
    • 依托单位:
    XBP1通过调控PSMA1介导巨噬细胞促进三阴性乳腺癌肿瘤免疫逃逸的机制研究
    • 批准号:
      JCZRLH202500052
    • 项目类别:
      省市级项目
    • 资助金额:
      --
    • 批准年份:
      2025
    • 负责人:
    • 依托单位:
    PSMA-PET时空动态评估HRR通路引导mCRPC患者PARPi精准分层与疗效预测研究